Back to top

Image: Bigstock

Why Vanda Pharmaceuticals (VNDA) Might Be a Diamond in the Rough

Read MoreHide Full Article

It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.

So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.

One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . This Medical - Biomedical and Genetics industry stock has actually seen estimates rise over the past month for the 19.6%. But that is not yet reflected in its price, as the stock lost 7.2% over the same time frame.

VANDA PHARMACT Price and Consensus

You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 29.1%, which should ultimately translate into price appreciation.

And if this isn’t enough, VNDA currently carries a Zacks Rank #1 (Strong Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance). You can see the complete list of today’s Zacks #1 Rank stocks here.

So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Vanda Pharmaceuticals. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for VNDA and that now might be an interesting buying opportunity.

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Vanda Pharmaceuticals Inc. (VNDA) - free report >>

Published in